Aurinia Pharmaceuticals Inc(AUPH) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.

Current Price

$10.15

RSI

18.041

Beta:

0.340594

September 30, 2020
8.3M
-32.6M

-87.391 %
0.862 %
-79.355 %
-103.169 %

$318,000
$463,000
$420,000
$173,000
$235,000
$278,000
-45.597 %
10.238 %
142.775 %
-35.838 %
-18.298 %

$-123,702,000
$-64,047,000
$-70,792,000
$-23,295,000
$-18,607,000
$-16,647,000
-48.225 %
10.531 %
-67.094 %
-20.124 %
-10.534 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.